Ocugen (FRA:2H51) Short Interest


FRA:2H51 Ocugen Inc FRA:2H51
20 GF Score
Price €1.31
GF Value €0.69
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ocugen Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:2H51 vs STRO, NGNE, CBIO: Short Interest Comparison

For the Biotechnology subindustry, Ocugen's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocugen Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocugen's Short Interest distribution charts can be found below:

* The bar in red indicates where Ocugen's Short Interest falls into.


FRA:2H51
20GF Score
Ocugen Inc FRA:2H51
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ocugen (FRA:2H51) Overvalued in 2026?

Based on GuruFocus' analysis, Ocugen stock appears to be overvalued. The current stock price of €1.31 is trading 89.9% above its estimated GF Value™ of €0.69. GuruFocus considers Ocugen to be Significantly Overvalued.

Key valuation signals for FRA:2H51:

  • Short Interest:
  • GF Value™: €0.69 vs. price of €1.31 (89.9% above fair value)
  • GF Score™: 20/100 with 4 warning signs

No single metric tells the full story. See the FRA:2H51 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ocugen Business Description

Address 11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
20GF Score

Get the complete analysis for FRA:2H51

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.31
Price
€0.69
GF Value